Khalid Islam
Gründer bei GAIN THERAPEUTICS, INC.
Vermögen: 5 Mio $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Matthias Alder | M | 59 |
GT Gain Therapeutics SA
GT Gain Therapeutics SA Pharmaceuticals: MajorHealth Technology GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland. | 3 Jahre |
Viktor Drvota | M | 59 | 9 Jahre | |
Manolo Bellotto | M | 53 |
GT Gain Therapeutics SA
GT Gain Therapeutics SA Pharmaceuticals: MajorHealth Technology GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland. | 6 Jahre |
Claude Nicaise | M | 71 |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | 3 Jahre |
Jeffrey Riley | M | 61 |
GT Gain Therapeutics SA
GT Gain Therapeutics SA Pharmaceuticals: MajorHealth Technology GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland. | 5 Jahre |
Robert Andrade | M | 49 | 15 Jahre | |
Gianluca Fuggetta | M | 35 | 2 Jahre | |
Marco Brughera | M | 70 | 12 Jahre | |
Adrian Haigh | M | 64 | 10 Jahre | |
Rostislav Raykov | M | 48 | 15 Jahre | |
Andrew Dickinson | M | 54 | 4 Jahre | |
Marc Martinell Pedemonte | M | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | 13 Jahre |
Mohammed Khoso Baluch | M | 66 | 2 Jahre | |
Casper Hansen | M | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | 11 Jahre |
Elisabet Gimbringer | F | 59 | 9 Jahre | |
Jodi Cook | M | 56 | 5 Jahre | |
Christina Carlson | F | - | 4 Jahre | |
Dov Goldstein | M | 56 | 3 Jahre | |
Mikael von Euw | M | - |
Sirius Healthcare Partners GmbH
Sirius Healthcare Partners GmbH Investment ManagersFinance Sirius Healthcare Partners GmbH provides independent advice to small and mid-cap healthcare companies, venture capital firms, institutional and private investors. The firm's services include strategic advisory, mergers and acquisition and financing advisory. It serves in the area of biotechnology, medical technology and diagnostics, platform technologies and healthcare markets. The company was founded by Subhasis Roy, Khalid Islam, Ernesto Mancosu, Werner Tschollar, Andreas Vogler and Mikael von Euw and is headquartered in Zurich, Switzerland. | - |
Hans-Peter Hasler | M | 68 | 3 Jahre | |
Eric Richman | M | 63 | 4 Jahre | |
Gwen Melincoff | M | 72 | 3 Jahre | |
Chris Rallis | M | 70 | 13 Jahre | |
Ernesto A. M. Mancosu | M | - |
Sirius Healthcare Partners GmbH
Sirius Healthcare Partners GmbH Investment ManagersFinance Sirius Healthcare Partners GmbH provides independent advice to small and mid-cap healthcare companies, venture capital firms, institutional and private investors. The firm's services include strategic advisory, mergers and acquisition and financing advisory. It serves in the area of biotechnology, medical technology and diagnostics, platform technologies and healthcare markets. The company was founded by Subhasis Roy, Khalid Islam, Ernesto Mancosu, Werner Tschollar, Andreas Vogler and Mikael von Euw and is headquartered in Zurich, Switzerland. | - |
Werner Tschollar | M | - |
Sirius Healthcare Partners GmbH
Sirius Healthcare Partners GmbH Investment ManagersFinance Sirius Healthcare Partners GmbH provides independent advice to small and mid-cap healthcare companies, venture capital firms, institutional and private investors. The firm's services include strategic advisory, mergers and acquisition and financing advisory. It serves in the area of biotechnology, medical technology and diagnostics, platform technologies and healthcare markets. The company was founded by Subhasis Roy, Khalid Islam, Ernesto Mancosu, Werner Tschollar, Andreas Vogler and Mikael von Euw and is headquartered in Zurich, Switzerland. | - |
Andreas Vogler | M | - |
Sirius Healthcare Partners GmbH
Sirius Healthcare Partners GmbH Investment ManagersFinance Sirius Healthcare Partners GmbH provides independent advice to small and mid-cap healthcare companies, venture capital firms, institutional and private investors. The firm's services include strategic advisory, mergers and acquisition and financing advisory. It serves in the area of biotechnology, medical technology and diagnostics, platform technologies and healthcare markets. The company was founded by Subhasis Roy, Khalid Islam, Ernesto Mancosu, Werner Tschollar, Andreas Vogler and Mikael von Euw and is headquartered in Zurich, Switzerland. | - |
Brett Pletcher | M | 56 | 4 Jahre | |
Karen Wagner | M | 54 |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | - |
Thierry Laugel | M | 57 |
Kurma Biofund FCPR
Kurma Biofund FCPR Investment ManagersFinance Kurma Biofund seeks investment opportunities in life science and biotechnology companies located in Europe. The investments are done in cooperation with medical institutes and universities such as Institut Pasteur and Institut Curie. Its investment size ranges between €0.10 and €6 million. | - |
Sílvia Pascual | F | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | 9 Jahre |
Carulla Tormo | M | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | 2 Jahre |
Sonia Maria Poli | M | 59 |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | 5 Jahre |
Pablo Cironi | M | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | 5 Jahre |
Jordi Petit Salamo | M | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | - |
Philippe Monteyne | M | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | 6 Jahre |
Elena Cubero-Jorda | F | - | - | |
Xavier Badia | M | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | - |
Marc Engelen | M | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | - |
Gerald Raymond | M | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | - |
Mark Gowland | M | 52 | 9 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
David M. Goldenberg | M | 85 | 36 Jahre | |
Laura Iris Ferro | M | 72 | 17 Jahre | |
Marina del Bue | F | 66 | 15 Jahre | |
Massimo Iacobelli | M | 64 | 16 Jahre | |
Harout Semerjian | M | 52 | - | |
Jim van Heusden | M | 53 | 2 Jahre | |
Michael Pehl | M | 60 | 2 Jahre | |
Niclas Adler | M | 53 | - | |
Michael R. Garone | M | 66 | 3 Jahre | |
Shiu Kin Yeung | M | 65 |
Imperial College London
| 5 Jahre |
Usama Malik | M | 49 | 3 Jahre | |
Behzad Aghazadeh | M | 52 | 3 Jahre | |
Amr Ali Baghdadi | M | - |
Imperial College London
| 5 Jahre |
Glenn L. Cooper | M | 71 | 4 Jahre | |
Salvatore Calabrese | M | 54 | 3 Jahre | |
Subhasis Roy | M | 55 |
Sirius Healthcare Partners GmbH
Sirius Healthcare Partners GmbH Investment ManagersFinance Sirius Healthcare Partners GmbH provides independent advice to small and mid-cap healthcare companies, venture capital firms, institutional and private investors. The firm's services include strategic advisory, mergers and acquisition and financing advisory. It serves in the area of biotechnology, medical technology and diagnostics, platform technologies and healthcare markets. The company was founded by Subhasis Roy, Khalid Islam, Ernesto Mancosu, Werner Tschollar, Andreas Vogler and Mikael von Euw and is headquartered in Zurich, Switzerland. | 9 Jahre |
Riccardo Palmisano | M | 65 | - | |
Tet Foh Wong | M | 63 |
Imperial College London
| 5 Jahre |
Laura Villa | F | - | - | |
Jared M. Freedberg | M | 55 | 2 Jahre | |
Charles Baum | M | 65 | 1 Jahre | |
Ana Maria Garcia-Collazo | M | - |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | 5 Jahre |
John Manzoni | M | 64 |
Imperial College London
| 5 Jahre |
Bobby Sandage | M | 70 | - | |
Scott Canute | M | 63 | 3 Jahre | |
Barbara Duncan | F | 59 | 1 Jahre | |
Charles Ballantyne | M | 64 | 1 Jahre | |
Peter Hutt | M | 89 | 3 Jahre | |
Nigel Ten Fleming | M | 71 |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | 5 Jahre |
Elmar Schnee | M | 65 | 2 Jahre | |
Mallory Morales | F | 40 | 2 Jahre | |
Terje Kalland | M | 73 | 4 Jahre | |
Mohammad Zaidi | M | - |
Imperial College London
| 4 Jahre |
John David Salter | M | 66 |
Imperial College London
| 8 Jahre |
Naser Naji Al-Trawneah | M | 60 |
Imperial College London
| 4 Jahre |
Matthew Pilkington | M | - |
Imperial College London
| 3 Jahre |
Nap Kai Cheung | M | 64 |
Imperial College London
| 4 Jahre |
Too Heng-Phon | M | 65 |
Imperial College London
| 4 Jahre |
Robert Vee-Lin Thong | M | 63 |
Imperial College London
| 3 Jahre |
Norton Jonathan | M | - |
Imperial College London
| 3 Jahre |
M. Fidelis Tedja Surya | M | 67 |
Imperial College London
| 4 Jahre |
Richard Philpott | M | - |
Imperial College London
| 3 Jahre |
Cholanat Yanaranop | M | 65 |
Imperial College London
| 1 Jahre |
Nicholas Paine | M | 59 |
Imperial College London
| 4 Jahre |
Mohamad Khalid bin Embong | M | 68 |
Imperial College London
| 4 Jahre |
Alexander Mark Burns | M | 61 |
Imperial College London
| 4 Jahre |
Luis Augusto Pacheco | M | - |
Imperial College London
| 3 Jahre |
Leong Meng Chu | M | 68 |
Imperial College London
| 4 Jahre |
Nigel A. J. Walls | M | 63 |
Imperial College London
| 4 Jahre |
Hans Anthony Kuropatwa | M | 65 |
Imperial College London
| 4 Jahre |
Pantelis A. Georgiadis | M | - |
Imperial College London
| 1 Jahre |
Garry Menzel | M | 59 |
Imperial College London
| 4 Jahre |
Nicholas Walker | M | 62 |
Imperial College London
| 4 Jahre |
Benson Tam | M | 61 |
Imperial College London
| 4 Jahre |
Richard Hillis | M | - |
Imperial College London
| 4 Jahre |
Alan Sherrard | M | - |
Imperial College London
| 1 Jahre |
Antonakis Antoniou | M | 69 |
Imperial College London
| 6 Jahre |
Howard Bell | M | - |
Imperial College London
| 3 Jahre |
Yong Sun Mah | M | 62 |
Imperial College London
| 4 Jahre |
Frank Millar | M | - |
Imperial College London
| 11 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 36 | 36,00% |
Vereinigtes Königreich | 32 | 32,00% |
Spanien | 14 | 14,00% |
Italien | 9 | 9,00% |
Deutschland | 5 | 5,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Khalid Islam
- Persönliches Netzwerk